nach oben

CNS Drugs

Erschienen in:

01.09.2012 | Adis Drug Clinical Q&A

Transdermal Granisetron: A Guide to Its Use in Preventing Nausea and Vomiting Induced by Chemotherapy

verfasst von: Gillian M. Keating, Sean T. Duggan, Monique P. Curran

Erschienen in: CNS Drugs | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Transdermal granisetron (Sancuso®) is effective in the prevention of nausea and vomiting in patients with cancer who are receiving moderately or highly emetogenic chemotherapy for 3–5 days. Transdermal granisetron is noninferior to oral granisetron in this indication, and is generally well tolerated in this indication. Thus, transdermal granisetron provides a convenient option for the prevention of chemotherapy-induced nausea and vomiting, with the potential to improve patient compliance.

National Comprehensive Cancer Network Clinical Practice Guideline in Oncology (NCCN Guidelines™): antiemesis (version 1.2012). Fort Washington (PA): National Comprehensive Cancer Network® Inc., 2011 Jul 20

Duggan ST, Curran MP. Transdermal granisetron. Drugs 2009; 69(18): 2597–605PubMedCrossRef

Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J 2008 Mar–Apr; 14(2): 85–93PubMedCrossRef

Hesketh PJ. Chemotherapy-induced nausea and vomiting. Engl J Med 2008 Jun 5; 358(23): 2482–94CrossRef

Multinational Association of Supportive Care in Cancer. MASCC/ESMO antiemetic guidelines 2011 [online]. Available from URL: http://data.memberclicks.com/site/mascc/MASCC_Guidelines_English_2011.pdf [Accessed 2012 May 25]

Sancuso® (granisetron transdermal system): US prescribing information. Bedminster: ProStrakan Inc., 2008 Jul

Nitti VW, Sanders S, Staskin DR, et al. Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology 2006 Apr; 67(4): 657–64PubMedCrossRef

Plosker GL, Goa KL. Granisetron: a review of its pharmacological properties and therapeutic use as an antiemetic. Drugs 1991; 42(5): 805–24PubMedCrossRef

Yarker YE, McTavish D. Granisetron: an update of its therapeutic use in nausea and vomiting induced by anti-neoplastic therapy. Drugs 1994; 48(5): 761–93PubMedCrossRef

10.

Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 2009; 69(5): 515–33PubMedCrossRef

11.

Sancuso 3.1 mg/24 hours transdermal patch: summary of product characteristics. London: European Medicines Agency, 2012 May 8

12.

Boccia RV, Gordan LN, Clark G, et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011 Oct; 19(10): 1609–17PubMedCrossRef

Titel: Transdermal Granisetron: A Guide to Its Use in Preventing Nausea and Vomiting Induced by Chemotherapy
verfasst von: Gillian M. Keating
Sean T. Duggan
Monique P. Curran
Publikationsdatum: 01.09.2012
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 9/2012
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/11209440-000000000-00000

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Transdermal Granisetron: A Guide to Its Use in Preventing Nausea and Vomiting Induced by Chemotherapy

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2012

Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder

Frovatriptan

Dose Response of Gabapentin Enacarbil versus Placebo in Subjects with Moderate-to-Severe Primary Restless Legs Syndrome

Topiramate as an Adjunctive Treatment in Patients with Refractory Status Epilepticus

Rasagiline: A Guide to Its Use in Parkinson’s Disease

Pharmacotherapy for Parents with Attention-Deficit Hyperactivity Disorder (ADHD)

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie